---
title: 'Executive Director, New Product Planning at IMVT Corporation'
canonical: 'https://feeny.ai/job/executive-director-new-product-planning-imvt-corporation-remote-hek53s90egtb'
type: 'job'
last_seen: '2026-10-30'
---

# Executive Director, New Product Planning at IMVT Corporation

- **Company:** IMVT Corporation
- **Location:** Remote
- **Compensation:** $280k–$320k
- **Work type:** remote
- **Posted:** 2026-10-29
- **Last confirmed live:** 2026-10-30
- **Apply:** https://job-boards.greenhouse.io/imvtcorporation/jobs/6238275004

## Job description

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As trailblazers in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs.

The Role:

The Executive Director of New Product Planning is responsible for new product opportunity assessments and the commercial strategy for lifecycle indications of IMVT-1402.  Reporting to the Chief Strategy Officer, this position leads commercial strategy and market development efforts for new products and follow-on indications from ideation through handoff to the launch team for build-out approximately 24 months pre-launch.  Leading their team and partnering with commercial, the Executive Director will work to identify and prioritize potential new indications and manage commercial strategy for indications in development.

Key Responsibilities:

New Product Planning

- Lead development of comprehensive commercial strategy and plan for follow-on indications in collaboration with cross-functional partners, including Target Product Profile development, situational analysis, market development strategy, data generation strategy, and initial value proposition.
- Commercial lead in cross functional project teams providing input into development decisions, ensuring alignment with market needs, competitive positioning, reimbursement considerations, and business objectives.
- Lead the development of an insight-driven commercial strategy for each brand indication by applying a strategic framework that uses key leverage points and strategic choices to begin to determine go to market approach.
- Lead commercial opportunity assessments for potential new product opportunities, follow-on indications, and provide commercial recommendations for potential investment or abandonment.
- Ensure execution of market development tactics, including KOL identification and engagement, foundational market research, and other prelaunch market shaping activities.
- Collaborate with Commercial leadership to ensure strategic cohesion and alignment in commercial approach or across indications.
- Regularly engage with and support the need for thought partnership with functional partners (clinical development, market research, market access, competitive intelligence, medical affairs, etc.).
- Communicate with the organization regarding indication strategy.
- Maintain expertise in each disease state, competitive landscape, and market dynamics, informing potential pivots in strategic and executional approaches as needed.
- Responsible for the management of the New Product Planning team and budget.

Requirements:

- BA/BS required; MBA and/or other relevant graduate degree preferred
- 15+ years of experience in a biotechnology or pharmaceutical organization. Marketing, commercial development/new product planning, data analysis and forecasting, product management, market development, new product launch, market access and pricing experience required
- Track record of enterprise and executive leadership influence - able to lead through ambiguity, align diverse stakeholders, and drive decisions across functions outside of direct reporting lines
- Exceptional communication skills; able to synthesize complex inputs into clear recommendations for executive leadership
- Demonstrated analytical and problem-solving skills, leading to the development of innovative marketing initiatives
- Analytical, creative, solution-oriented, collaborative, and decisive

Work Environment:

- Remote; Available for travel to Immunovant’s NYC office as requested
- Dynamic, interactive, fast-paced, and entrepreneurial environment
- Domestic or international travel is required (up to 20%)

Salary range for posting $280,000—$320,000 USD

Compensation is based on a number of factors, including market location, and may vary depending on job-related knowledge, skills, and experience. Equity and other forms of compensation may be provided as part of a total compensation package, in addition to a full range of medical, dental, vision, 401k, and other benefits, including unlimited paid time off and parental leave.

## About IMVT Corporation

## Company Overview
- **One-liner**: A clinical-stage immunology company developing innovative anti-FcRn therapies to enable normal lives for people with autoimmune diseases.
- **Entity Type**: Public (Nasdaq: IMVT)
- **Headquarters**: Durham, North Carolina, United States
- **Founded**: Not publicly available
- **Founders**: Not publicly available

## Core Business
- **Primary industry**: Biotechnology / Autoimmune disease therapeutics
- **Target customers**: Patients with IgG-mediated autoimmune diseases; healthcare providers; payers (B2B/B2C mix via prescription drugs)
- **Mission or purpose statement**: “Dedicated to enabling normal lives for people with autoimmune diseases” [immunovant.com](https://www.immunovant.com/)

## Products & Services
- **[IMVT-1402 (imeroprubart)]**: A novel, fully human monoclonal antibody that targets FcRn to reduce pathogenic IgG autoantibodies. Designed as a subcutaneous injection with a simple autoinjector (YpsoMate®). In clinical development for six indications: Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren’s disease (SjD), and cutaneous lupus erythematosus (CLE). [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)
- **[Batoclimab (first-generation anti-FcRn)]**: Development discontinued across all indications after Phase 3 TED trials did not meet primary endpoints; learnings inform IMVT-1402 program. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Market Standing
- **Valuation/Market Cap**: Not disclosed in available sources (publicly traded on Nasdaq; refer to real-time market data).
- **Key Metric**: Clinical-stage company with no approved products or revenue; total funding and operating expenses are detailed in SEC filings but not summarized here.
- **Notable Investors/Partners**: HanAll Biopharma (collaboration on anti-FcRn antibodies); Ypsomed AG (auto-injector YpsoMate®). [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)
- **Growth Signals**: Six ongoing clinical programs (including potentially registrational trials); deep IgG reductions (~80% with weekly 600 mg IMVT-1402) suggesting best-in-class potential; Phase 1 safety data showing no/minimal albumin reduction or LDL cholesterol increases. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Competitive Advantages
- **Potential best-in-class efficacy**: IMVT-1402 achieves deeper IgG reductions than competitor anti-FcRn antibodies, correlating with improved clinical outcomes.
- **Favorable safety profile**: No or minimal off-target effects on albumin and LDL cholesterol, unlike some FcRn inhibitors.
- **Convenient administration**: Self-administered subcutaneous autoinjector (YpsoMate®) expected at launch, improving patient adherence.
- **Broad pipeline**: Six indications in development across endocrinology, rheumatology, neurology, and dermatology, with potential for more.

## Strategic Focus
- Execute pivotal trials for IMVT-1402 in GD, D2T RA, MG, CIDP, SjD, and CLE.
- Leverage learnings from batoclimab program to accelerate IMVT-1402 development.
- Plan to assess new indications for IMVT-1402 beyond the initial six.
- Continue to build commercial capabilities for eventual launch. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Why Work Here
- **Culture**: Emphasizes “Hire and Retain Only the Very Best,” “One Team, Shared Success,” “Ownership Mentality,” and “Patients Are Waiting” – a mission-driven, high-performance environment. [About Us](https://www.immunovant.com/about-us)
- **Remote/Hybrid Policy**: Job listings show a mix of remote and hybrid roles (e.g., “Remote” for many positions, “Hybrid - NYC” for commercial roles). [Careers](https://www.immunovant.com/join-us/explore-careers)
- **Notable Perks**: Merit-based recognition, focus on impact and results, creative problem-solving encouraged. [About Us](https://www.immunovant.com/about-us)
- **Engineering/Science Culture**: Clinical-stage biotech with cutting-edge FcRn technology; opportunities in clinical development, biometrics, quality assurance, and commercial roles. [Careers](https://www.immunovant.com/join-us/explore-careers)

## Sources
1. [Immunovant Corporate Website](https://www.immunovant.com/)
2. [About Us – Values and Culture](https://www.immunovant.com/about-us)
3. [Company Information – Investor Relations](https://www.immunovant.com/investors/company-information)
4. [Explore Careers – Job Listings](https://www.immunovant.com/join-us/explore-careers)
5. [10-K SEC Filing (May 20, 2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Other roles at IMVT Corporation

- [Associate Director, Biostatistics](https://feeny.ai/job/associate-director-biostatistics-imvt-corporation-remote-dgj2yvz4mm9k)
- [Senior Manager, Medical Communications](https://feeny.ai/job/senior-manager-medical-communications-imvt-corporation-remote-s03pz93xa8tp)
- [Executive Director, Marketing](https://feeny.ai/job/executive-director-marketing-imvt-corporation-remote-sc5ja0w76sbv)
- [Director, Infrastructure & Data Platforms](https://feeny.ai/job/director-infrastructure-data-platforms-imvt-corporation-remote-vcb6ytpndm32)
- [Director, Supply Chain Product Planning](https://feeny.ai/job/director-supply-chain-product-planning-imvt-corporation-remote-a4ek4z6agfre)
- [Senior Director, Corporate & Commercial IT Business Systems](https://feeny.ai/job/senior-director-corporate-commercial-it-business-systems-imvt-corporation-remote-vw2vm2e990w9)
- [Senior Manager, Statistical Programming](https://feeny.ai/job/senior-manager-statistical-programming-imvt-corporation-remote-6q5z9h7nwxvn)
- [Director, Financial Planning & Analysis](https://feeny.ai/job/director-financial-planning-analysis-imvt-corporation-remote-2xtk0zhd4zbr)
- [Executive Assistant](https://feeny.ai/job/executive-assistant-imvt-corporation-new-york-m7dv0wr8rkjs) — New York, NY
- [Director, Medical Science Liaison (MSL)](https://feeny.ai/job/director-medical-science-liaison-msl-imvt-corporation-southeast-cnykwbftkpjw) — Southeast, United States